Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinomaTanguy Y. Seiwert, Amanda Psyrri, Jared Weiss et al.|Cancer Immunology Immunotherapy|2024Cited by 9
266 Tumour mutation burden (TMB) and efficacy outcomes in the phase III DANUBE study of advanced urothelial carcinoma (UC)Sophie Wildsmith, Jill Walker, Anne L’Hernault et al.|Regular and Young Investigator Award Abstracts|2020Cited by 7
SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).Toni K. Choueiri, Laurence Albigès, Daniel Yick Chin Heng et al.|Journal of Clinical Oncology|2020Cited by 5
MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.Laurence Albigès, Sabina Signoretti, Daniel Yick Chin Heng et al.|Journal of Clinical Oncology|2020Cited by 4